Modality
Small Molecule
MOA
IL-13i
Target
EGFR
Pathway
Proteasome
Fabry
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Jan 2026
Phase 1Current
NCT05877103
507 pts·Fabry
2018-02→2026-01·Recruiting
507 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-152mo agoPh2 Data· Fabry
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P1/2
Recruit…
Catalysts
Ph2 Data
2026-01-15 · 2mo ago
Fabry
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05877103 | Phase 1/2 | Fabry | Recruiting | 507 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR |